Deepnoid and Peptron Hit Daily Limit, L&C Bio Falls on Rights Offering[K-Bio Pulse]

[Hong Ju-yeon, Edaily Reporter] South Korea's pharmaceutical and biotechnology sector received a boost on Aug. 3 as the KOSDAQ market posted strong gains. Buying momentum intensified, triggering the 16th KOSDAQ buy-side circuit breaker of the year at 10:28 a.m. Deepnoid and Peptron both surged to the daily upper limit, driven by Deepnoid's first commercial contract for its generative medical AI solution and expectations that Peptron could join Eli Lilly's GLP-1 supply chain. Meanwhile, L&C Bio traded lower following the announcement of a large-scale rights offering worth approximately KRW 140.6 billion.Deepnoid Stock Chart (Source: KG Zeroin MP Doctor)Deepnoid Hits Daily Limit on First Supply Contract for Generative Medical AIAccording to KG Zeroin MP DOCTOR on Aug. 3, Deepnoid closed at KRW 1,599, up KRW 369 (30.00%) from the previous trading day.The stock rallied after the company announced a supply agreement with Pusan National University Hospital for M4CXR, its generative AI-based chest X-ray preliminary report generation solution. The agreement marks the first commercial deployment of M4CXR since it received medical device approval from South Korea's Ministry of Food and D...